Interventions for treating bisphosphonate-related... (2016 study) Skip to main content
Cochrane Review The Cochrane database of systematic reviews 2016 Cochrane

Interventions for treating bisphosphonate-related osteonecrosis of the jaw (BRONJ).

Rollason V, Laverrière A, MacDonald LC, Walsh T, Tramèr MR, Vogt-Ferrier NB, The Cochrane database of systematic reviews, 2016

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

The authors searched medical databases for randomised controlled trials of any treatment for bisphosphonate-related osteonecrosis of the jaw (BRONJ), a rare but serious bone problem in the jaw linked to bisphosphonate drugs.

What They Found

This Cochrane review found only one small trial at high risk of bias, and it could not confirm or refute whether hyperbaric oxygen therapy (HBOT) helps people with BRONJ. The trial randomised 49 participants, most of whom had cancer, to standard care (surgery, antibiotics and oral rinses) or standard care plus HBOT at 2 atmospheres twice a day for 40 treatments. At three months, the HBOT group was more likely to have improvement (risk ratio 1.94, 95% confidence interval 1.01 to 3.74), but there was no clear difference in the outcome "healed" (risk ratio 3.60, 95% confidence interval 0.87 to 14.82). There was no clear difference in improvement or healing at six, 12 and 18 months or last contact, and the trial gave no information on adverse events.

What This Means for Canadian Patients

For people with BRONJ, the review found a lack of randomised trial evidence to guide any treatment. The one HBOT trial could not confirm or refute that HBOT works, and the evidence quality was rated very low. Patients should discuss treatment options with their oral-maxillofacial surgeon.

Canadian Relevance

No direct Canadian connection identified.

Study Limitations

The only included trial was underpowered and at high risk of bias because of no blinding, cross-over of participants between groups, and very high attrition (50% at 12 months and 80% at 18 months, against a planned 24 months of follow-up).

This plain-language summary was generated with AI assistance from the study's abstract; it has not been individually reviewed by a clinician. Always consult the source study and a qualified healthcare professional. See our editorial policy.

Was this summary helpful?

Study Details

Study Type Cochrane Review
Category Radiation Injury
Source Pubmed
PubMed ID 26919630
Year Published 2016
Journal The Cochrane database of systematic reviews
MeSH Terms Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Combined Modality Therapy; Humans; Hyperbaric Oxygenation; Mouthwashes; Pain Measurement; Randomized Controlled Trials as Topic; Standard of Care; Time Factors

Cite This Study

Share

This study relates to Delayed Radiation Injury. Read the full clinical overview, the evidence base, and Canadian treatment access for this condition.

Find a Canadian Clinic Treating Radiation Injury

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.

Last updated: April 1, 2026 | Reviewed by: Canada Hyperbarics Editorial Team | Editorial process | Research sources | Counts & methodology